<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02924220</url>
  </required_header>
  <id_info>
    <org_study_id>2016-038</org_study_id>
    <secondary_id>ID-RCB number : 2016-A00650-51</secondary_id>
    <nct_id>NCT02924220</nct_id>
  </id_info>
  <brief_title>Genetic Susceptibility and Biomarkers in Listeriosis</brief_title>
  <acronym>MONALISAGENBIO</acronym>
  <official_title>Genetic Susceptibility and Biomarkers in Listeriosis (MONALISA-GENBIO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Pasteur</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Pasteur</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Listeriosis is a rare, severe foodborne infection caused by the bacterium Listeria
      monocytogenes (Lm). It manifests as septicemia, central nervous system (CNS) infection and
      maternal-fetal (MF) infection. Its associated overall mortality is very high, above of 30%. A
      better knowledge on the factors involved in its occurrence and in clinical manifestations is
      therefore needed to improve outcome.

      A number of frequent acquired risk factors for listeriosis have been identified, such as
      pregnancy, diabetes, cancer, HIV infection, and immunosuppressive therapies. However, no
      genetic study on host susceptibility to listeriosis in humans has been performed so far, in
      the absence of prospective collection of patients' samples. Also, listeriosis diagnosis is
      based on Lm culture from clinical samples. This method lacks sensitivity, and the
      contribution of biomarkers to listeriosis diagnosis and prognosis has not been evaluated.

      The Multicentric Observational NAtional Analysis of Listeriosis and Listeria (MONALISA), is
      the first national case-control prospective study on listeriosis. It is implemented since
      2009 and enrolls all culture-proven cases declared to the NRCL: and collects for each patient
      clinical and biological data and biological samples. Controls with comparable background and
      presentation are also included. 818 cases have been included (427 S, 252 CNS and 107 MN) over
      3.5 years, along with 456 controls.

      The aim of the study is to identify human genetic susceptibility factors to listeriosis,
      biomarkers to improve its diagnosis and prognosis (survival or death), and thereby help
      improve management of patients with listeriosis.

      Samples from the completed cohort will be analyzed : SNPs genotyping and exam sequencing;
      biomarkers a identification in serum and plasma of patients and controls by simultaneous
      multi-analyte and metabolomic profiling.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Context :

      Listeriosis is a rare, severe foodborne infection caused by the bacterium Listeria
      monocytogenes (Lm). It manifests as septicemia, central nervous system (CNS) infection and
      maternal-fetal (MF) infection. Its associated overall mortality is very high, above of 30%. A
      better knowledge on the factors involved in its occurrence and in clinical manifestations is
      therefore needed to improve outcome. Surveillance of human listeriosis in France relies on
      the mandatory reporting of cases and the submission of the corresponding Lm strains to the
      National Reference Centre for Listeria (NRCL).

      A number of acquired risk factors for listeriosis have been identified, such as pregnancy,
      age, cirrhosis, renal insufficiency, diabetes, cancer, HIV infection, transplantation and
      immunosuppressive therapies. If listeriosis is rare, the exposure to Lm is universal. The
      high prevalence of known risk factors in the general population and the low occurrence of the
      disease suggest that unknown parameters, such as host genetic factors, contribute to the
      susceptibility to listeriosis. This is supported by animal studies, which have shown that
      genes involved in innate and cell-based immunity are critical to control listeriosis.
      However, no genetic study on host susceptibility to listeriosis in humans has been performed
      so far, in the absence of prospective collection of patients' samples.

      Listeriosis diagnosis is based on Lm culture from clinical samples. This specific method
      lacks sensitivity, and the usefulness of PCR or serological assays have not been assessed in
      prospective case-control studies. Biomarkers are useful tools to diagnose infections and
      assess their severity, but their contribution to listeriosis diagnosis and prognosis has not
      been evaluated.

      The Multicentric Observational NAtional Analysis of Listeriosis and Listeria (MONALISA), a
      national case-control prospective study on listeriosis, was launched in 2009. It enrolls all
      culture-proven cases declared to the NRCL: clinical and biological data and biological
      samples (plasma, serum, PBMC) are collected at inclusion for each patient. Controls with
      comparable background and presentation are also included. 818 cases have been included (427
      S, 252 CNS and 107 MN) over 3.5 years, along with 456 controls.

      Hypothesis :

        -  host genetic variation plays an important role in determining susceptibility to
           listeriosis and its clinical manifestations. Common host genetic variation in the human
           population may play a role in susceptibility in association with known acquired risk
           factors. Rare variants may also explain severe manifestations of listeriosis, such as
           death, severe persistent neurological impairment and fetal loss, in the absence of risk
           factors.

        -  biomarker patterns can assess and predict infection and infection severity. Immune
           responses may be tracked as a biological signature of invasive listeriosis

        -  biomarkers patterns could hopefully correlate with genotypic characterization as a
           phenotypic reflection of a genetically inadequate / missing link hampering the proper
           coordination of the immune response to Lm.

      Methods :

        -  SNP arrays genotyping of the whole cohort

        -  Whole-exome sequencing of the whole cohort to identify rare variants

        -  Biomarkers identification in serum and plasma of patients and controls by simultaneous
           multi-analyte and metabolomic profiling:

      The cohort is already constituted.

      Expected results :

      Better understanding of major biomedical aspects of listeriosis, namely host genetic
      susceptibility factors and diagnostic/prognostic biomarkers.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">February 16, 2017</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Characterisation of genetic susceptibility markers for infection as a whole and for each form and/or for the severity of infection</measure>
    <time_frame>3 years</time_frame>
    <description>Characterisation of genetic susceptibility markers for infection as a whole and for each form and/or for the severity of infection by whole exome sequencing and whole genome genotyping for all MONALISA cases and controls</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarkers identification in serum and plasma of patients and controls</measure>
    <time_frame>3 years</time_frame>
    <description>Biomarkers identification in serum and plasma of patients and controls by simultaneous multi-analyte and metabolomic profiling:
-Characterisation of a biological signature of listeriosis as a whole and for each form of infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers identification in serum and plasma of patients and controls</measure>
    <time_frame>3 years</time_frame>
    <description>Biomarkers identification in serum and plasma of patients and controls by simultaneous multi-analyte and metabolomic profiling:
-Characterisation of the severity of infection (prognosis): death, fetal loss, neurological persisting impairment.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1274</enrollment>
  <condition>Listeriosis</condition>
  <arm_group>
    <arm_group_label>Case patients</arm_group_label>
    <description>Patients with culture-proven listeriosis. Case patients are classified in 3 groups :
Septicemic infections: isolation of Lm in blood cultures.
CNS infections: isolation of Lm in cerebrospinal fluid, or brain stereotaxic biopsy, or by isolation of Lm in the blood with concomitant meningitis, or radiological encephalitis, rhombencephalitis, brain abscess or meningitis.
MF infections: defined by isolation of Lm in any maternal/fetal/neonatal bacteriological sample.
All patients have given their written consent to participate in the MONALISA cohort and for the collection of a blood sample including DNA samples for DNA analyses will be included in the MONALISA GENBIO study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control patients</arm_group_label>
    <description>Patients without listeriosis but compatible clinical presentation. Control patients are divided in 3 groups.
Septicemic controls: febrile patient with same co-morbidities as septicemic cases.
CNS controls: patient with any neurological symptom leading to the empiric prescription of amoxicillin at meningeal dosage because of listeriosis presumption.
MF controls: febrile pregnant patient without obvious focal infection.
All patients have given their written consent to participate in the MONALISA cohort and for the collection of a blood sample including DNA samples for DNA analyses will be included in the MONALISA GENBIO study.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biological samples (serum, plasma, mononuclear cells and DNA) previously collected from cases
      patients and control patients included in the MONALISA cohort.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients already recruited in the MONALISA study will be included. The MONALISA study
        is the first prospective case-control study focused on invasive listeriosis. Cases are
        patients with culture-proven listeriosis. Controls are patients without listeriosis but
        compatible clinical presentation.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients have given their written consent to participate in the MONALISA cohort
             and for the collection of a blood sample including DNA samples for DNA analyses.

        Exclusion Criteria:

          -  Patients included in the MONALISA cohort without biological sample available.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Lecuit</last_name>
    <role>Study Director</role>
    <affiliation>Institut Pasteur</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Pasteur, Unit√© de Biologie des Infections</name>
      <address>
        <city>Paris</city>
        <zip>75724 Cedex 15</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2016</study_first_submitted>
  <study_first_submitted_qc>October 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2016</study_first_posted>
  <last_update_submitted>August 1, 2017</last_update_submitted>
  <last_update_submitted_qc>August 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease Susceptibility</mesh_term>
    <mesh_term>Genetic Predisposition to Disease</mesh_term>
    <mesh_term>Listeriosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

